Annals of Breast Cancer and Therapy

Case Report Pages 77-80

Olaparib for Simultaneous Occurrence of Breast Cancer and Ovarian Cancer with BRCA1

Authors: Rina Tanaka, Akinori Sasaki, Shoko Sano and Ken Mizokami

Abstract: Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, is associated with a high tumor response rate among patients with breast cancer susceptibility (BRCA) genes. The efficacy and safety of olaparib in the treatment of patients with simultaneous occurrence of breast and ovarian cancers have not been reported on. We report the case of a 57-year-old woman who was treated for multiple lung metastases after resection of breast cancer. She was newly diagnosed with ovarian cancer, and a BRCA1 mutation was detected by genomic profiling for BRCA 1 and BRCA 2.

| | |